Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.65 USD
+0.47 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
DCPH 14.65 +0.47(3.31%)
Will DCPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DCPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DCPH
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
DCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
Other News for DCPH
Diving Into Deciphera Pharmaceuticals
DCPH Makes Notable Cross Below Critical Moving Average
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Piper Sandler Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)
Commit To Purchase Deciphera Pharmaceuticals At $7.50, Earn 15.7% Annualized Using Options